Overview

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs such as CC-5013 and dexamethasone may be effective in treating primary systemic amyloidosis. PURPOSE: This phase II trial is studying CC-5013 to see how well it works with or without dexamethasone in treating patients with primary systemic amyloidosis.
Phase:
Phase 2
Details
Lead Sponsor:
Vaishali Sanchorawala
Collaborator:
Celgene Corporation
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Lenalidomide